(Reuters) -Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility in Wilson, North Carolina, aiding production of new therapies.

The new facility will expand J&J's production of biologic medicines to treat cancer, immunity-related and neurological diseases, the company said.

The drugmaker aims to launch or file for more than 70 new therapies and expanded treatment options for patients by 2030.

J&J is investing in capacity to ensure a resilient supply chain for the future, said Dapo Ajayi, vice president at J&J's innovative medicine supply chain.

The company expects to commence construction of the facility in the first half of 2025, J&J said, adding that it will employ about 400 full-time staff when it is fully operational.

(Reporting by Sriparna Roy and Mariam Sunny in Bengaluru; Editing by Leroy Leo and Alan Barona)